$ASMB
Assembly Biosciences Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021054499 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q4
Revenue $6.254M $0.00 $1.037M
YoY Change -81.93% -100.0% -78.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.655M $6.917M $7.170M
YoY Change -43.07% -26.96% -33.8%
% of Gross Profit
Research & Development $18.47M $16.75M $33.51M
YoY Change -31.43% -28.2% 48.14%
% of Gross Profit
Depreciation & Amortization $119.0K $117.0K $310.0K
YoY Change 19.0% 17.0% 181.82%
% of Gross Profit
Operating Expenses $25.13M $23.67M $40.68M
YoY Change -34.95% -27.84% 21.61%
Operating Profit -$18.88M -$23.67M
YoY Change -459.72%
Interest Expense $72.00K $71.00K $220.0K
YoY Change -89.25% -89.71% -74.42%
% of Operating Profit
Other Income/Expense, Net $72.00K $71.00K
YoY Change -89.73%
Pretax Income -$18.80M -$23.60M -$39.42M
YoY Change 461.28% -424.55% 41.65%
Income Tax
% Of Pretax Income
Net Earnings -$18.80M -$23.60M -$39.42M
YoY Change 461.45% -424.55% 45.54%
Net Earnings / Revenue -300.66% -3801.16%
Basic Earnings Per Share -$0.41 -$0.55 -$1.11
Diluted Earnings Per Share -$412.6K -$0.55 -$1.11
COMMON SHARES
Basic Shares Outstanding 45.57M 42.88M
Diluted Shares Outstanding 45.57M 42.88M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $180.9M $199.1M $216.4M
YoY Change -23.96% -12.18% -21.03%
Cash & Equivalents $70.76M $59.52M $59.44M
Short-Term Investments $110.1M $139.6M $157.0M
Other Short-Term Assets $6.548M $6.184M $6.900M
YoY Change 33.63% 21.25% 27.78%
Inventory
Prepaid Expenses
Receivables $769.0K $297.0K $1.230M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $188.2M $205.6M $224.5M
YoY Change -23.61% -12.57% -20.61%
LONG-TERM ASSETS
Property, Plant & Equipment $8.014M $8.847M $1.600M
YoY Change 320.9% 328.84% -12.57%
Goodwill $12.64M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $9.180M
YoY Change
Other Assets $1.922M $6.093M $6.392M
YoY Change -67.97% 17.17% 279.57%
Total Long-Term Assets $60.75M $56.58M $58.76M
YoY Change 1.43% -5.23% 2.86%
TOTAL ASSETS
Total Short-Term Assets $188.2M $205.6M $224.5M
Total Long-Term Assets $60.75M $56.58M $58.76M
Total Assets $249.0M $262.1M $283.3M
YoY Change -18.72% -11.08% -16.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.628M $2.866M $4.598M
YoY Change 64.25% -20.39% 165.63%
Accrued Expenses $5.457M $4.320M $11.99M
YoY Change -26.3% -28.23% 44.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.93M $13.91M $24.43M
YoY Change -11.14% -19.46% -0.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.869M $13.90M $15.70M
YoY Change -58.12% 75.96% -60.45%
Total Long-Term Liabilities $6.869M $13.90M $15.70M
YoY Change -58.12% 75.96% -60.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.93M $13.91M $24.43M
Total Long-Term Liabilities $6.869M $13.90M $15.70M
Total Liabilities $24.33M $30.34M $42.68M
YoY Change -32.04% 9.59% -36.01%
SHAREHOLDERS EQUITY
Retained Earnings -$501.6M
YoY Change 14.14%
Common Stock $742.4M
YoY Change 4.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $224.6M $231.8M $240.6M
YoY Change
Total Liabilities & Shareholders Equity $249.0M $262.1M $283.3M
YoY Change -18.72% -11.08% -16.67%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q4
OPERATING ACTIVITIES
Net Income -$18.80M -$23.60M -$39.42M
YoY Change 461.45% -424.55% 45.54%
Depreciation, Depletion And Amortization $119.0K $117.0K $310.0K
YoY Change 19.0% 17.0% 181.82%
Cash From Operating Activities -$18.88M -$21.81M -$25.27M
YoY Change -277.46% -5.62% 23.09%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.000K -$1.750M
YoY Change -100.5% 17400.0%
Acquisitions
YoY Change
Other Investing Activities $20.07M -$3.083M $22.46M
YoY Change -140.24% -104.01% -123.64%
Cash From Investing Activities $20.07M -$3.091M $20.71M
YoY Change -140.24% -104.04% -121.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.06M 6.156M 5.690M
YoY Change 1097.02% 548.0% -95.86%
NET CHANGE
Cash From Operating Activities -18.88M -21.81M -25.27M
Cash From Investing Activities 20.07M -3.091M 20.71M
Cash From Financing Activities 10.06M 6.156M 5.690M
Net Change In Cash 11.24M -18.75M 1.130M
YoY Change -129.28% -134.47% -94.83%
FREE CASH FLOW
Cash From Operating Activities -$18.88M -$21.81M -$25.27M
Capital Expenditures $0.00 $2.000K -$1.750M
Free Cash Flow -$18.88M -$21.81M -$23.52M
YoY Change -277.46% -3.95% 14.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 asmb Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4444000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
29000000
CY2020Q4 us-gaap Goodwill
Goodwill
12638000
CY2020Q4 us-gaap Assets
Assets
283254000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4598000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
9180000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1600000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9131000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6392000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11987000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-302000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-507000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22691000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35506042
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4470000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4296000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-461000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
216000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42725109
us-gaap Profit Loss
ProfitLoss
-69598000
us-gaap Profit Loss
ProfitLoss
-22734000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
346000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
377000
us-gaap Share Based Compensation
ShareBasedCompensation
3292000
us-gaap Share Based Compensation
ShareBasedCompensation
18106000
asmb Accretion And Amortization Of Investments In Marketable Debt Securities
AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities
-398000
asmb Accretion And Amortization Of Investments In Marketable Debt Securities
AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities
80000
asmb Noncash Rent Expense
NoncashRentExpense
2940000
asmb Noncash Rent Expense
NoncashRentExpense
3463000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1625000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1970000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-120000
asmb Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
-700000
asmb Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
-375000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-6490000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-877000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6254000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28061000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2856000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11316000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11579000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59444000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74034000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37688000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3382000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46732000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70760000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58311000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
126000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1912000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3078000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
470000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
857000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
107480000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
153022000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
132200000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
165252000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
12500000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
35595000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
34999000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47355000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1445000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
144000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
467000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50207000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50351000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1063000
asmb Remeasurement Of Lease Liabilities Arising From Modification Of Right Of Use Assets
RemeasurementOfLeaseLiabilitiesArisingFromModificationOfRightOfUseAssets
788000
asmb Remeasurement Of Lease Liabilities Arising From Modification Of Right Of Use Assets
RemeasurementOfLeaseLiabilitiesArisingFromModificationOfRightOfUseAssets
0
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
231794000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10055000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
843000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-262000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6202000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3349000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
270549000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
240578000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50207000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
144000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3332000
us-gaap Net Income Loss
NetIncomeLoss
-69598000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
224645000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
273217000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1445000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
467000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
43000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18111000
us-gaap Net Income Loss
NetIncomeLoss
-22734000
asmb Number Of Approved Products
NumberOfApprovedProducts
0
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
270549000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates for the cost-based input of revenue recognition and standalone selling price estimates for allocation of transaction price to performance obligations, revenue recognition, estimates of costs incurred but not yet invoiced for clinical trial accruals, recoverability and useful lives of our long-lived assets, the estimated fair value of our indefinite-lived intangible assets, the estimated fair value of our reporting unit for purposes of evaluating goodwill impairment, provisions for income taxes, amounts receivable under collaboration agreements, measurement of operating lease liabilities, and the fair value of stock options, stock appreciation rights, and restricted stock units (RSUs) granted to employees, directors, and consultants.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Company’s estimates and could cause actual results to differ materially from those estimates and assumptions.</p>
CY2021Q2 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
2109140
CY2021Q3 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
315102
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-18803000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3349000
us-gaap Net Income Loss
NetIncomeLoss
-69598000
us-gaap Net Income Loss
NetIncomeLoss
-22734000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45569276
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35506042
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42725109
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35321393
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11987000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7354525
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7537699
CY2021Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
187230000
CY2021Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
CY2021Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
16000
CY2021Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
187215000
CY2020Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
211017000
CY2020Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
7000
CY2020Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
4000
CY2020Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
211020000
CY2021Q3 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2020Q4 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4871000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7016000
CY2021Q3 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
232000
CY2020Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
4164000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
354000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
807000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5457000
asmb Restructuring And Related Cost Incurred Cost Benefit
RestructuringAndRelatedCostIncurredCostBenefit
-1348000
CY2021Q3 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
6430000
CY2021Q3 asmb Restructuring And Related Cost Incurred Cost Benefit
RestructuringAndRelatedCostIncurredCostBenefit
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
asmb Restructuring And Related Cost Incurred Cost Benefit
RestructuringAndRelatedCostIncurredCostBenefit
-1348000
CY2020Q3 asmb Restructuring And Related Cost Incurred Cost Benefit
RestructuringAndRelatedCostIncurredCostBenefit
0
asmb Restructuring And Related Cost Incurred Cost Benefit
RestructuringAndRelatedCostIncurredCostBenefit
0
us-gaap Restructuring Charges
RestructuringCharges
1611000
us-gaap Payments For Restructuring
PaymentsForRestructuring
5543000
CY2021Q3 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
232000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
900000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 asmb Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
300000000.0
CY2020Q3 asmb Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
300000000.0
CY2021Q3 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
315102
asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
2424242
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2423634
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2423634
asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2020Q3 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1900000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3000000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4600000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
6600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000.0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8987000
asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1592000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6048000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3292000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18106000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
12000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
6254000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2733000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37048000
asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
40000000
asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
68061000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8987000
CY2021Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
800000
asmb Performance Milestone Payment
PerformanceMilestonePayment
0
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7200000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6800000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
902000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1164000
us-gaap Operating Lease Cost
OperatingLeaseCost
2940000
us-gaap Operating Lease Cost
OperatingLeaseCost
3463000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
32000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
101000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
227000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
301000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
312000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
409000
us-gaap Variable Lease Cost
VariableLeaseCost
1063000
us-gaap Variable Lease Cost
VariableLeaseCost
1101000
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
38000
us-gaap Sublease Income
SubleaseIncome
104000
CY2021Q3 us-gaap Lease Cost
LeaseCost
1208000
CY2020Q3 us-gaap Lease Cost
LeaseCost
1674000
us-gaap Lease Cost
LeaseCost
4126000
us-gaap Lease Cost
LeaseCost
4865000
us-gaap Operating Lease Payments
OperatingLeasePayments
2856000
us-gaap Operating Lease Payments
OperatingLeasePayments
3382000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
126000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1063000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.097
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.092
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
927000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3643000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3491000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8074000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
839000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7235000

Files In Submission

Name View Source Status
0001564590-21-054499-index-headers.html Edgar Link pending
0001564590-21-054499-index.html Edgar Link pending
0001564590-21-054499.txt Edgar Link pending
0001564590-21-054499-xbrl.zip Edgar Link pending
asmb-10q_20210930.htm Edgar Link pending
asmb-10q_20210930_htm.xml Edgar Link completed
asmb-20210930.xsd Edgar Link pending
asmb-20210930_cal.xml Edgar Link unprocessable
asmb-20210930_def.xml Edgar Link unprocessable
asmb-20210930_lab.xml Edgar Link unprocessable
asmb-20210930_pre.xml Edgar Link unprocessable
asmb-ex101_170.htm Edgar Link pending
asmb-ex102_169.htm Edgar Link pending
asmb-ex311_8.htm Edgar Link pending
asmb-ex312_7.htm Edgar Link pending
asmb-ex321_9.htm Edgar Link pending
asmb-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending